SPRB

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Spruce Biosciences reported positive pre-BLA meetings with the FDA and confirmed that its TA-ERT BLA submission remains on track for Q4 2026Aug 24, 2026
• Spruce Biosciences reported positive Type B meetings with the FDA regarding TA-ERT for Sanfilippo syndrome type BFeb 18, 2026
• Spruce Biosciences receives U.S. FDA breakthrough therapy designation for Tralesinidase Alfa enzyme replacement therapy in Sanfilippo syndrome type B (MPS IIIB)Oct 6, 2025
• Spruce Biosciences announces integrated long-term clinical data of Tralesinidase Alfa enzyme replacement therapy demonstrating profound and durable efficacy and safety in Sanfilippo syndrome type B patientsAug 15, 2025
• HMNC Brain Health and Spruce Biosciences announce first patient dosed in Phase 2 TAMARIND trial for major depressive disorderJul 23, 2025